ICCC (ImmuCell) Cyclically Adjusted Revenue per Share: $2.90 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICCC ImmuCell Corp ICCC
54 GF Score
Price $10.13
GF Value $6.91
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Cyclically Adjusted Revenue per Share?

ImmuCell ICCC +4.00% 54 Cyclically Adjusted Revenue per Share is $2.90 as of Jun. 2026. GuruFocus rates ICCC with a GF Score™ of 54/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ImmuCell's adjusted revenue per share for the three months ended in Jun. 2026 was $0.782. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.90 for the trailing ten years ended in Jun. 2026.

During the past 12 months, ImmuCell's average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ImmuCell was 6.30% per year. The lowest was -3.90% per year. And the median was 2.00% per year.

As of today (2026-08-20), ImmuCell's current stock price is $10.13. ImmuCell's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $2.90. ImmuCell's Cyclically Adjusted PS Ratio of today is 3.49.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ImmuCell was 5.08. The lowest was 1.23. And the median was 2.66.


ImmuCell  (NAS:ICCC) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ImmuCell's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.13/2.90
=3.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ImmuCell was 5.08. The lowest was 1.23. And the median was 2.66.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ImmuCell Cyclically Adjusted Revenue per Share Related Terms


ImmuCell Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ImmuCell's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell Cyclically Adjusted Revenue per Share Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.55 2.73 2.79 2.87 2.81

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.87 2.85 2.81 2.87 2.90

ICCC vs COYA, ENTX, BDTX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, ImmuCell's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ImmuCell's Cyclically Adjusted PS Ratio falls into.


ICCC
54GF Score
ImmuCell Corp ICCC
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ImmuCell's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.782/333.9520*333.9520
=0.782

Current CPI (Jun. 2026) = 333.9520.

ImmuCell Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.457 241.428 0.632
201612 0.461 241.432 0.638
201703 0.717 243.801 0.982
201706 0.361 244.955 0.492
201709 0.402 246.819 0.544
201712 0.613 246.524 0.830
201803 0.526 249.554 0.704
201806 0.550 251.989 0.729
201809 0.393 252.439 0.520
201812 0.534 251.233 0.710
201903 0.778 254.202 1.022
201906 0.376 256.143 0.490
201909 0.412 256.759 0.536
201912 0.503 256.974 0.654
202003 0.681 258.115 0.881
202006 0.411 257.797 0.532
202009 0.516 260.280 0.662
202012 0.519 260.474 0.665
202103 0.569 264.877 0.717
202106 0.585 271.696 0.719
202109 0.659 274.310 0.802
202112 0.703 278.802 0.842
202203 0.770 287.504 0.894
202206 0.499 296.311 0.562
202209 0.619 296.808 0.696
202212 0.505 296.797 0.568
202303 0.445 301.836 0.492
202306 0.456 305.109 0.499
202309 0.697 307.789 0.756
202312 0.658 306.746 0.716
202403 0.936 312.332 1.001
202406 0.701 314.175 0.745
202409 0.736 315.301 0.780
202412 0.867 315.605 0.917
202503 0.898 319.799 0.938
202506 0.714 322.561 0.739
202509 0.609 324.800 0.626
202512 0.843 324.054 0.869
202603 1.145 330.213 1.158
202606 0.782 333.952 0.782

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $2.90 mean?
ImmuCell (ICCC) has a Cyclically Adjusted Revenue per Share of $2.90 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ImmuCell and its competitors.
Is ImmuCell's Cyclically Adjusted Revenue per Share too high?
ImmuCell's current Cyclically Adjusted Revenue per Share is $2.90. Overall, ImmuCell has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Cyclically Adjusted Revenue per Share compare to COYA and ENTX?
ImmuCell's Cyclically Adjusted Revenue per Share of $2.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ImmuCell and its competitors. ImmuCell's current Cyclically Adjusted Revenue per Share is $2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.13 — trading 46.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $2.90. ImmuCell's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ImmuCell (ICCC), the current Cyclically Adjusted Revenue per Share is $2.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (ICCC) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of $10.13 is trading 46.6% above its estimated GF Value™ of $6.91. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for ICCC:

  • Cyclically Adjusted Revenue per Share: $2.90
  • GF Value™: $6.91 vs. price of $10.13 (46.6% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ImmuCell Business Description

Other Exchanges IUL:Germany
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
54GF Score

Get the complete analysis for ICCC

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.13
Price
$6.91
GF Value